Aberdeen Asset Management PLC UK raised its stake in shares of Humana Inc. (NYSE:HUM) by 87.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 159,210 shares of the insurance provider’s stock after purchasing an additional 74,305 shares during the period. Aberdeen Asset Management PLC UK owned 0.11% of Humana worth $38,309,000 at the end of the most recent reporting period.
Other hedge funds also recently modified their holdings of the company. Guardian Life Insurance Co. of America increased its position in Humana by 0.7% during the first quarter. Guardian Life Insurance Co. of America now owns 575 shares of the insurance provider’s stock worth $119,000 after purchasing an additional 4 shares during the last quarter. Independent Portfolio Consultants Inc. increased its position in Humana by 22.1% during the second quarter. Independent Portfolio Consultants Inc. now owns 519 shares of the insurance provider’s stock worth $125,000 after purchasing an additional 94 shares during the last quarter. Point72 Asia Hong Kong Ltd acquired a new position in Humana during the first quarter worth approximately $128,000. Fiduciary Trust Co. acquired a new position in Humana during the second quarter worth approximately $135,000. Finally, Westbourne Investment Advisors Inc. acquired a new position in Humana during the second quarter worth approximately $205,000. 95.14% of the stock is owned by hedge funds and other institutional investors.
Humana Inc. (HUM) opened at 256.56 on Friday. The firm’s 50-day moving average is $247.64 and its 200-day moving average is $229.85. The company has a market capitalization of $37.08 billion, a P/E ratio of 21.11 and a beta of 0.87. Humana Inc. has a 1-year low of $163.50 and a 1-year high of $259.47.
Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.08 by $0.41. The business had revenue of $13.53 billion for the quarter, compared to the consensus estimate of $13.61 billion. Humana had a net margin of 3.37% and a return on equity of 15.85%. During the same quarter last year, the company posted $2.30 earnings per share. Equities research analysts predict that Humana Inc. will post $11.55 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Tuesday, August 29th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.60 annualized dividend and a dividend yield of 0.62%. Humana’s payout ratio is 13.06%.
ILLEGAL ACTIVITY WARNING: “Humana Inc. (HUM) Shares Bought by Aberdeen Asset Management PLC UK” was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.themarketsdaily.com/2017/09/10/humana-inc-hum-shares-bought-by-aberdeen-asset-management-plc-uk.html.
In other news, SVP Brian P. Leclaire sold 4,971 shares of the firm’s stock in a transaction on Wednesday, June 28th. The shares were sold at an average price of $240.00, for a total value of $1,193,040.00. Following the sale, the senior vice president now owns 14,258 shares in the company, valued at $3,421,920. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider William Kevin Fleming sold 3,071 shares of the firm’s stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $250.98, for a total transaction of $770,759.58. Following the completion of the sale, the insider now owns 7,681 shares in the company, valued at approximately $1,927,777.38. The disclosure for this sale can be found here. In the last 90 days, insiders sold 60,566 shares of company stock worth $15,326,746. 0.80% of the stock is currently owned by corporate insiders.
HUM has been the subject of several research reports. ValuEngine upgraded shares of Humana from a “hold” rating to a “buy” rating in a research note on Friday, September 1st. UBS AG reiterated a “neutral” rating and set a $250.00 price objective (up from $237.00) on shares of Humana in a research note on Wednesday, August 9th. BidaskClub upgraded shares of Humana from a “sell” rating to a “hold” rating in a research note on Thursday, August 10th. Cantor Fitzgerald reiterated a “neutral” rating and set a $223.00 price objective (up from $200.00) on shares of Humana in a research note on Thursday, August 3rd. Finally, Morgan Stanley boosted their price objective on shares of Humana from $269.00 to $276.00 and gave the stock an “overweight” rating in a research note on Thursday, August 17th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $244.35.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.